secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0000950170-23-021769
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside terminates Cowen ATM facility, enters new up to $50M at-the-market equity deal with Cantor
--------------------------------------------------------------------------------

- Terminated prior Cowen Sales Agreement effective May 12, 2023; $35.8M net raised from ~19M shares since 2017.
- Entered new Controlled Equity Offering with Cantor Fitzgerald to sell up to $50M of common stock at-the-market.
- Cantor will receive up to 3% commission on gross sales; Company not obligated to sell any shares.
- New facility provides ongoing equity capital access for the biotech firm.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023021769/0000950170-23-021769-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017023021769/clsd-20230512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021769

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer